REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

Exenatide Research Evidence

The Exenatide evidence base: trials, journals, and what the data does not yet show.

RE
Compiled from published research · Continuously updated

First-in-Class Legacy

Approved in 2005 as Byetta, exenatide was the first GLP-1 receptor agonist available to patients, predating semaglutide by over a decade. The extended-release microsphere formulation, Bydureon, was approved in 2012, reformulating the same molecule into a once-weekly depot injection. Because it's been in clinical use the longest of any GLP-1, it has an extensive long-term safety record.

Regulatory and Legal Status

Exenatide is prescription-only and FDA-approved for type 2 diabetes under both the Byetta and Bydureon brand names. It is a legitimate pharmaceutical and should only be obtained through a licensed prescriber and pharmacy.

All Exenatide sections

Retatrutide

fat loss & metabolismAgrade

An investigational triple GIP/GLP-1/glucagon receptor agonist producing some of the largest average weight reductions reported for a single agent.

Liraglutide

fat loss & metabolismSgrade

A once-daily GLP-1 receptor agonist — the class predecessor to semaglutide and tirzepatide, still widely prescribed under Victoza and Saxenda.

Orforglipron

fat loss & metabolismSgrade

The first oral, non-peptide GLP-1 receptor agonist pill with no food or water restrictions — FDA-approved in 2026 as Foundayo.

Put the whole protocol
in one place.

Download nowGet Now